Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/− binimetinib or alpelisib

BACKGROUND: Treatment strategies inhibiting BRAF in combination with EGFR have been developed in patients with BRAF(V600E) mutant metastatic colorectal cancer, but intrinsic and secondary resistance remains a challenge. We aimed to investigate which genetic alterations cause intrinsic non-response a...

Descripción completa

Detalles Bibliográficos
Autores principales: Huijberts, Sanne C. F. A., Boelens, Mirjam C., Bernards, Rene, Opdam, Frans L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782586/
https://www.ncbi.nlm.nih.gov/pubmed/33204026
http://dx.doi.org/10.1038/s41416-020-01147-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782586/
https://www.ncbi.nlm.nih.gov/pubmed/33204026
http://dx.doi.org/10.1038/s41416-020-01147-2

Ejemplares similares